Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted a non-qualified stock option award to purchase an aggregate of 200,000 shares of its Class A common stock to one new employee under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan (the "2023 Inducement Plan"). The stock options were granted as inducements material to the new employee becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $2.09 per share, which is equal to the closing price of Quantum-Si's Class A common stock on The Nasdaq Global Market on August 15, 2023, the date of grant of the options. Each option will vest over a four-year period, with 25% of the shares vesting on the last day of the calendar quarter that is 12 months after the employee's start date and the remaining shares vesting monthly over the following 36-months, subject to the employee's continued employment with Quantum-Si on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.


These press releases may also interest you

at 23:25
Sungrow, a global leading PV inverter and energy storage system provider, has recently issued its 2023 Sustainability Report. This marks the 9th consecutive year that the company has publicly reported on its dedication to sustainable development....

at 23:15
In August 2023, VXI inaugurated a new delivery center in Hyderabad, its first site in India. "Building something from the ground up, in a new geography, is very, very difficult. You need a...

at 23:15
With a skilled, multilingual workforce, modern infrastructure, and a supportive business environment, Egypt has become an ideal offshore outsourcing destination. "Egypt is a vibrant hub for both U.S. and European-based businesses." - Ahmed Bahgat,...

at 23:00
BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. , today announced the final May 2024 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on May 23,...

at 22:15
Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has been awarded the GUINNESS WORLD RECORDSTM title for the fastest robot to solve a puzzle cube using a robot equipped with high-speed, high-precision factory automation (FA)...

at 22:06
Tencent (00700.HK) is awarding 13 exceptional teams that won the first phase of its groundbreaking CarbonX Program, which is aimed at boosting promising new climate technologies. The winners, which emerged from a pool of 30 finalists and more than...



News published on and distributed by: